Tags

Type your tag names separated by a space and hit enter

[Cytomegalovirus reactivation after allogeneic stem cell transplantation reduces the risk of relapse in patients with acute myeloid leukemia].
Rinsho Ketsueki. 2015 Jul; 56(7):825-30.RK

Abstract

Cytomegalovirus (CMV) infection is still a major infectious complication after allogeneic hematopoietic cell transplantation (HCT). Recently, CMV reactivation was reported to be associated with a decreased risk of relapse in patients with acute myeloid leukemia (AML). We herein retrospectively evaluated the impact of early CMV reactivation on the incidence of disease relapse after allo-HCT using the database of the Transplant Registry Unified Management Program (TRUMP) at the JSHCT. Patients who underwent their first allo-HCT from HLA-matched related or unrelated donors between 2000 and 2009, and who survived without disease relapse until day 100 after transplantation, were analyzed. CMV reactivation was associated with a decreased cumulative incidence of relapse among patients with AML, but not in patients with other hematological malignancies in our study. However, this benefit was nullified by the increased rate of non-relapse mortality. The underlying mechanism is unclear, but the immunological reaction against CMV reactivation plays an essential role in this association. Thus, immune augmentation treatment options including vaccination and adoptive T-cell transfer might be useful for taking advantage of the efficacy of CMV reactivation while minimizing the increase in non-relapse mortality.

Authors+Show Affiliations

Center for Cellular and Molecular Medicine, Kyushu University Hospital.

Pub Type(s)

English Abstract
Journal Article

Language

jpn

PubMed ID

26251145

Citation

Takenaka, Katsuto. "[Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Reduces the Risk of Relapse in Patients With Acute Myeloid Leukemia]." [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, vol. 56, no. 7, 2015, pp. 825-30.
Takenaka K. [Cytomegalovirus reactivation after allogeneic stem cell transplantation reduces the risk of relapse in patients with acute myeloid leukemia]. Rinsho Ketsueki. 2015;56(7):825-30.
Takenaka, K. (2015). [Cytomegalovirus reactivation after allogeneic stem cell transplantation reduces the risk of relapse in patients with acute myeloid leukemia]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 56(7), 825-30. https://doi.org/10.11406/rinketsu.56.825
Takenaka K. [Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Reduces the Risk of Relapse in Patients With Acute Myeloid Leukemia]. Rinsho Ketsueki. 2015;56(7):825-30. PubMed PMID: 26251145.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cytomegalovirus reactivation after allogeneic stem cell transplantation reduces the risk of relapse in patients with acute myeloid leukemia]. A1 - Takenaka,Katsuto, PY - 2015/8/8/entrez PY - 2015/8/8/pubmed PY - 2015/11/7/medline SP - 825 EP - 30 JF - [Rinsho ketsueki] The Japanese journal of clinical hematology JO - Rinsho Ketsueki VL - 56 IS - 7 N2 - Cytomegalovirus (CMV) infection is still a major infectious complication after allogeneic hematopoietic cell transplantation (HCT). Recently, CMV reactivation was reported to be associated with a decreased risk of relapse in patients with acute myeloid leukemia (AML). We herein retrospectively evaluated the impact of early CMV reactivation on the incidence of disease relapse after allo-HCT using the database of the Transplant Registry Unified Management Program (TRUMP) at the JSHCT. Patients who underwent their first allo-HCT from HLA-matched related or unrelated donors between 2000 and 2009, and who survived without disease relapse until day 100 after transplantation, were analyzed. CMV reactivation was associated with a decreased cumulative incidence of relapse among patients with AML, but not in patients with other hematological malignancies in our study. However, this benefit was nullified by the increased rate of non-relapse mortality. The underlying mechanism is unclear, but the immunological reaction against CMV reactivation plays an essential role in this association. Thus, immune augmentation treatment options including vaccination and adoptive T-cell transfer might be useful for taking advantage of the efficacy of CMV reactivation while minimizing the increase in non-relapse mortality. SN - 0485-1439 UR - https://www.unboundmedicine.com/medline/citation/26251145/[Cytomegalovirus_reactivation_after_allogeneic_stem_cell_transplantation_reduces_the_risk_of_relapse_in_patients_with_acute_myeloid_leukemia]_ L2 - https://dx.doi.org/10.11406/rinketsu.56.825 DB - PRIME DP - Unbound Medicine ER -